ABX464

• CAT Number: I000987
• CAS Number: 1258453-75-6
• Molecular Formula: C16H10ClF3N2O
• Molecular Weight: 338.714
• Purity: ≥95%
• Synonyms: ABX-464; SPL-464; ABX 464; SPL 464; ABX464; SPL464;8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
• Target: HIV replication inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4°Cfor short term (days to weeks), or -20 °C for long term (months).
• IUPAC Name: 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine
• InChI: InChI=1S/C16H10ClF3N2O/c17-13-3-1-2-10-4-9-14(22-15(10)13)21-11-5-7-12(8-6-11)23-16(18,19)20/h1-9H,(H,21,22)
• InChIKey: OZOGDCZJYVSUBR-UHFFFAOYSA-N
• SMILES: C1=CC2=C(C(=C1)Cl)N=C(C=C2)NC3=CC=C(C=C3)OC(F)(F)F

ABX464 (CAT: I000987) is a small molecule drug that has garnered significant attention for its potential antiviral and anti-inflammatory properties. It works by selectively inhibiting the production of viral RNA, thereby preventing the replication of certain viruses, including the human immunodeficiency virus (HIV). ABX464 also exhibits anti-inflammatory effects by modulating the expression of specific inflammatory genes. This dual mechanism of action makes ABX464 a promising candidate for the treatment of viral infections and inflammatory diseases. Ongoing clinical studies are exploring its efficacy and safety in various indications, including HIV/AIDS and inflammatory bowel disease.

Reference

1: Berkhout B, van der Velden YU. ABX464: a good drug candidate instead of a
magic bullet. Retrovirology. 2015 Jul 28;12:64. doi: 10.1186/s12977-015-0189-x.
PubMed PMID: 26215448; PubMed Central PMCID: PMC4515925.
2: Campos N, Myburgh R, Garcel A, Vautrin A, Lapasset L, Nadal ES,
Mahuteau-Betzer F, Najman R, Fornarelli P, Tantale K, Basyuk E, Séveno M,
Venables JP, Pau B, Bertrand E, Wainberg MA, Speck RF, Scherrer D, Tazi J. Long
lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated
viral RNA biogenesis. Retrovirology. 2015 Apr 9;12:30. doi:
10.1186/s12977-015-0159-3. PubMed PMID: 25889234; PubMed Central PMCID:
PMC4422473.
3: Scherrer D, Rouzier R, Cardona M, Barrett PN, Steens JM, Gineste P, Murphy RL,
Tazi J, Ehrlich HJ. Randomized Trial of Food Effect on Pharmacokinetic Parameters
of ABX464 Administered Orally to Healthy Male Subjects. Antimicrob Agents
Chemother. 2016 Dec 27;61(1). pii: e01288-16. doi: 10.1128/AAC.01288-16. Print
2017 Jan. PubMed PMID: 27799203; PubMed Central PMCID: PMC5192114.
4: Scherrer D, Rouzier R, Noel Barrett P, Steens JM, Gineste P, Murphy RL, Tazi
J, Ehrlich HJ. Pharmacokinetics and tolerability of ABX464, a novel
first-in-class compound to treat HIV infection, in healthy HIV-uninfected
subjects. J Antimicrob Chemother. 2017 Mar 1;72(3):820-828. doi:
10.1093/jac/dkw458. PubMed PMID: 27999038.
5: Steens JM, Scherrer D, Gineste P, Barrett PN, Kuanchai S, Winai R, Ruxrungtham
K, Tazi J, Murphy R, Ehrlich H. Safety, Pharmacokinetics and_Antiviral Activity
of a Novel HIV Antiviral, ABX464, in Treatment- Naïve HIV Infected Subjects: a
Phase II Randomized, Controlled Study. Antimicrob Agents Chemother. 2017 May 15.
pii: AAC.00545-17. doi: 10.1128/AAC.00545-17. [Epub ahead of print] PubMed PMID:
28507108.